MarketPulse

Haduvio

2 articles
BenzingaBenzinga··Na

Trevi Therapeutics Prices $150M Stock Offering as It Advances Chronic Cough Treatment

Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.
TRVIstock offeringclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Trevi Therapeutics Raises $150M to Advance Nalbuphine Program for Chronic Cough

Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.
TRVIclinical-stagepublic offering